Hormone therapy for breast cancer
Following Beatson's publications in 1896, various modalities of endocrine therapy applied to breast cancer have been developed. Endocrine treatment has greatly contributed to the improvement of the disease's prognosis. Tamoxifen has established itself as a first choice adjuvant therapy for patients with tumors expressing hormone receptors. Over the last decade, third generation aromatase inhibitors have demonstrated their efficacy amongst menopausal patients, alone or in combination with tamoxifen. Efficacy of these medications is dependent on patient's compliance. This article proposes a synthesis of the main knowledges available in the field of breast cancer endocrine therapy.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
Revue medicale de Liege - 66(2011), 5-6 vom: 30. Mai, Seite 367-71 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Hormonothérapie du cancer du sein |
|---|
| Beteiligte Personen: |
Lifrange, E [VerfasserIn] |
|---|
| Themen: |
Antineoplastic Agents, Hormonal |
|---|
| Anmerkungen: |
Date Completed 27.09.2011 Date Revised 26.08.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM210610832 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM210610832 | ||
| 003 | DE-627 | ||
| 005 | 20231224011957.0 | ||
| 007 | tu | ||
| 008 | 231224s2011 xx ||||| 00| ||fre c | ||
| 028 | 5 | 2 | |a pubmed24n0702.xml |
| 035 | |a (DE-627)NLM210610832 | ||
| 035 | |a (NLM)21826978 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Lifrange, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hormone therapy for breast cancer |
| 246 | 3 | 3 | |a Hormonothérapie du cancer du sein |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 27.09.2011 | ||
| 500 | |a Date Revised 26.08.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Following Beatson's publications in 1896, various modalities of endocrine therapy applied to breast cancer have been developed. Endocrine treatment has greatly contributed to the improvement of the disease's prognosis. Tamoxifen has established itself as a first choice adjuvant therapy for patients with tumors expressing hormone receptors. Over the last decade, third generation aromatase inhibitors have demonstrated their efficacy amongst menopausal patients, alone or in combination with tamoxifen. Efficacy of these medications is dependent on patient's compliance. This article proposes a synthesis of the main knowledges available in the field of breast cancer endocrine therapy | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antineoplastic Agents, Hormonal |2 NLM | |
| 650 | 7 | |a Aromatase Inhibitors |2 NLM | |
| 700 | 1 | |a Andre, C |e verfasserin |4 aut | |
| 700 | 1 | |a Bleret, V |e verfasserin |4 aut | |
| 700 | 1 | |a Collignon, J |e verfasserin |4 aut | |
| 700 | 1 | |a Coucke, P |e verfasserin |4 aut | |
| 700 | 1 | |a Cusumano, P |e verfasserin |4 aut | |
| 700 | 1 | |a Desreux, J |e verfasserin |4 aut | |
| 700 | 1 | |a Herman, P |e verfasserin |4 aut | |
| 700 | 1 | |a Jerusalem, G |e verfasserin |4 aut | |
| 700 | 1 | |a Kridelka, F |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, M |e verfasserin |4 aut | |
| 700 | 1 | |a Rorive, A |e verfasserin |4 aut | |
| 700 | 1 | |a Van Cauwenberge, J-R |e verfasserin |4 aut | |
| 700 | 1 | |a Colin, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale de Liege |d 1947 |g 66(2011), 5-6 vom: 30. Mai, Seite 367-71 |w (DE-627)NLM000044490 |x 0370-629X |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2011 |g number:5-6 |g day:30 |g month:05 |g pages:367-71 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2011 |e 5-6 |b 30 |c 05 |h 367-71 | ||